
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): May 15, 2007

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Virginia
(State or Other Jurisdiction
of Incorporation)

001-13467
(Commission File Number)

56-1641133
(IRS Employer
Identification No.)

601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)

Registrant's telephone number, including area code: **(804) 648-3820**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On May 15, 2007, Commonwealth Biotechnologies, Inc. (the “Company”) entered into a definitive agreement (the “Agreement”) with Tripos, Inc. (“Tripos”) regarding the sale of Tripos’ Discovery Research Products and Services business (“TDR”).

Under the terms of the Agreement:

- The Company has made to Tripos a payment of \$350,000, which is non-refundable and represents the entire cash portion of the purchase price payable by the Company.
- Tripos will receive all receipts of TDR, up to \$1,800,000, arising out of accounts receivable currently on the books of TDR and certain bookings that have not yet been billed. This amount is in payment of outstanding advances of \$878,711 made since March 11, 2007, with the remainder being additional purchase consideration.
- At closing, Tripos will forgive all intercompany loans and advances incurred by TDR prior to March 19, 2007.
- Tripos may make up to £100,000 of additional advances which, if made, would be repaid by TDR prior to June 30, 2007 without reduction of the amounts described above.
- The Company will be responsible for severance costs of certain executive officers of TDR that have severance or employment contracts with Tripos.

Closing under the Agreement is expected to occur within the next several weeks, subject to satisfaction of certain customary conditions set forth in the Agreement, including completion of a sale-leaseback transaction with the Southwest England Regional Development Authority (“SWERDA”) and payment and release of certain obligations to England’s Department of Trade and Industry (“DTI”). Under the terms of these arrangements, which are expected to be finalized in the near future, TDR would sell its principal building to SWERDA for a consideration of £2.6 million, enter a twelve year lease of this building, with breaks at successive three year intervals, escrow two years’ rent in the amount of £330,000, and pay £591,000 to DTI in full satisfaction of repayment obligations of TDR of £1.54 million that have been guaranteed by Tripos.

In addition, certain third party consents are required, as well as compliance with certain provision of England’s Companies Act that apply to transactions that are structured using target company assets.

The above description of the Agreement does not purport to be a complete statement of the parties’ rights and obligations thereunder and the transactions contemplated thereby. The Agreement is included as Exhibit 10.1 to this Report and the foregoing description is qualified in its entirety by reference to the exhibit.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements concerning, among other things, the Company's future prospects, including: (1) the Company's ability to complete the purchase of TDR; (2) the Company's ability to complete the SWERDA sale-leaseback transaction; (3) the Company's ability to obtain the release of certain obligations from DTI; and (4) the Company's ability to obtain required third-party consents. These statements are based upon numerous assumptions that the Company cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), including, without limitations, those factors set forth in the Company's Form 10-KSB for the fiscal year ended December 31, 2006, and from time to time in the Company's periodic filings with the SEC. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, the Company does not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS, APPOINTMENTS OF OFFICERS, COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On May 19, 2007, the Company accepted the resignation of Gerald P. Krueger as a director of the Company. At the time of his resignation Dr. Krueger served on the Nominating Committee and the Audit Committee of the Company's Board of Directors. Dr. Causey's resignation did not result from a disagreement with the Company, as such term is defined in 17 CFR 240.36-7, relating to the Company's operations, policies or practices.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

- (a) Financial statements of businesses acquired.

Not Applicable.

- (b) Pro forma financial information.

Not Applicable.

- (c) Shell company transactions.

Not Applicable.

- (d) Exhibits.

10.1 Stock Purchase and Sale Agreement, dated May 15, 2007, by and among Tripos, Inc., Tripos UK Holdings Limited and CBI

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Paul D'Sylva, Ph.D.

Paul D'Sylva
Chief Executive Officer

Dated: May 15, 2007

EXHIBIT INDEX

Number	Description of Exhibit
10.1	Stock Purchase and Sale Agreement, dated May 15, 2007, by and among Tripos, Inc., Tripos UK Holdings Limited and CBI
99.1	Press release, dated May 15, 2007, announcing definitive agreement for CBI to acquire Tripos Discovery Research Ltd

EXHIBIT 10.1

For further information contact:
Dr Paul D'Sylva
CEO
Commonwealth Biotechnologies, Inc.
858 699 0298

Dr. John P McAlister
CEO
Tripos, Inc.
314 616.4473

STOCK PURCHASE AND SALE AGREEMENT

by and among

**Tripos, Inc.,
a Utah corporation,
Tripos UK Holdings Limited,
a private limited company incorporated in England,**

and

**Commonwealth Biotechnologies, Inc.,
a Virginia corporation**

Dated as of May 11, 2007

TABLE OF CONTENTS

	<u>Page</u>
ARTICLE 1	1
PURCHASE AND SALE OF SHARES	1
1.1. <u>Sale and Delivery of Shares</u>	1
ARTICLE 2	1
<u>PURCHASE PRICE</u>	1
2.1. <u>Payment of Initial Consideration.</u>	1
2.2. <u>Payment of Additional Consideration</u>	2
ARTICLE 3	2
<u>REPRESENTATIONS AND WARRANTIES OF SELLER</u>	2
3.2 <u>Capitalization.</u>	2
3.3 <u>Corporate Authority and Approvals.</u>	3
3.4 <u>Title to Shares and Assets.</u>	3
3.5 <u>Government Filings; No Violations or Conflicts</u>	3
3.6 <u>Litigation</u>	3
3.7 <u>Brokers.</u>	3
ARTICLE 4	6
<u>REPRESENTATIONS AND WARRANTIES OF PURCHASER</u>	6
4.1 <u>Organization and Authority.</u>	6
4.2 <u>Compliance with Other Instruments.</u>	6
4.3 <u>Brokers.</u>	6
ARTICLE 5	7
<u>COVENANTS OF PURCHASER</u>	7
5.1 <u>Additional Advances.</u>	7
5.2 <u>Compliance with English Financial Assistance Laws.</u>	7
5.3 <u>Employee Matters.</u>	7
5.4 <u>Filing Assistance.</u>	7
5.5 <u>Use of Name.</u>	7
ARTICLE 6	8
6.1 <u>Representations and Warranties.</u>	8
6.2 <u>Absence of Litigation.</u>	8
6.3 <u>Consents and Approvals.</u>	8
6.4 <u>SWERDA Transaction.</u>	8
6.5 <u>DTI Repayment and Consent.</u>	9
6.6 <u>Equipment Lessor Consent.</u>	9
6.7 <u>License Agreement.</u>	9
ARTICLE 7	9
<u>CONDITIONS PRECEDENT TO SELLER'S OBLIGATIONS</u>	9
7.1 <u>Representations and Warranties.</u>	9
7.2 <u>Absence of Litigation.</u>	10
7.3 <u>Consents and Approvals.</u>	10
7.4 <u>SWERDA Transaction.</u>	10
7.5 <u>DTI Repayment and Consent.</u>	10
7.6 <u>U.S. Employees.</u>	10
7.7 <u>UK Executives.</u>	10
7.8 <u>Board Approval.</u>	10
7.9 <u>Security Interest.</u>	10
7.10 <u>Identified Receivables.</u>	10
7.11 <u>Financial Assistance Matters.</u>	11
<u>ARTICLE 8</u>	11
<u>CLOSING</u>	11
8.1 <u>Closing.</u>	11

8.2	<u>Deliveries by Parent and Seller.</u>	11
8.3	<u>Deliveries by Purchaser.</u>	11
<u>ARTICLE 9</u>		12
<u>MISCELLANEOUS</u>		12
9.1	<u>Survival of Representations and Warranties.</u>	12
9.2	<u>Publicity.</u>	12
9.3	<u>Commercially Reasonable Efforts.</u>	12
9.4	<u>Further Acts and Assurances.</u>	12
9.5	<u>Notices.</u>	12
9.6	<u>Construction.</u>	13
9.7	<u>Knowledge.</u>	13
9.8	<u>Attachments.</u>	14
9.9	<u>Parties Bound by Agreement.</u>	14
9.10	<u>Counterparts.</u>	14
9.11	<u>Headings.</u>	14
9.12	<u>Modification and Waiver.</u>	14
9.13	<u>Severability.</u>	14
9.14	<u>Access to Records.</u>	14
9.15	<u>Entire Agreement.</u>	15
9.16	<u>Certain Definitions.</u>	15

STOCK PURCHASE AND SALE AGREEMENT

THIS STOCK PURCHASE AND SALE AGREEMENT (this “Agreement”), made and entered into this 11th day of May, 2007, by and among Tripos, Inc., a Utah corporation (“Parent”), Tripos UK Holdings Limited, a wholly-owned subsidiary of Parent and a private limited company incorporated in England (“Seller”), and, Commonwealth Biotechnologies, Inc., a Virginia corporation (“Purchaser”).

RECITALS

1. Seller is the owner of a discovery research business (the “Business”) conducted through the operation of its wholly-owned subsidiary Tripos Discovery Research Ltd. (“TDR”);

2. Purchaser desires to purchase from Seller, and Seller desires to sell to Purchaser, all of the issued and outstanding share capital of TDR comprising 101,000 shares of £1.00 each (the “Acquired Shares”), which transfer shall cause the Purchaser to own one hundred percent (100%) of TDR, all for the purchase price and subject to the terms and conditions set forth in this Agreement; and

NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

ARTICLE 1

PURCHASE AND SALE OF SHARES

1.1. Sale and Delivery of Shares. Subject to the terms and conditions hereof, Seller agrees to sell, assign, transfer and deliver, or cause to be sold, assigned, transferred and delivered, to Purchaser, and Purchaser agrees to purchase and accept from Seller at the “Closing” (as hereinafter defined), all of Seller’s right, title and interest in and to the Acquired Shares for the Purchase Price (as defined in, and subject to adjustment in accordance with, Article 2 hereof).

ARTICLE 2

PURCHASE PRICE

2.1. Payment of Initial Consideration. The aggregate consideration for the Acquired Shares (the “Purchase Price”) shall be three hundred fifty thousand dollars US (\$350,000.00) (the “Initial Consideration”), plus addition consideration computed pursuant to Section 2.2 (the “Additional Consideration”). Simultaneously with the execution of this Agreement, the Purchaser has delivered to the Seller the Initial Consideration, as a non-refundable deposit pursuant to this Agreement.

2.2. Payment of Additional Consideration.

(a) "Additional Consideration" means the proceeds, to a maximum aggregate sum of one million eight hundred thousand dollars US (\$1,800,000) collected by or on behalf of TDR on or after March 20, 2007 and through and including July 15, 2007 under invoices by TDR to Tripos, Inc. in its capacity as the sole distributor for TDR to the end-user customer outstanding on the date of this Agreement or created from the date hereof through and including the Closing Date, which shall also include receivables arising under an order from Schering Plough order #0000303433 with an order date of February 28, 2007, regardless of whether such amounts are invoiced before or after the Closing Date (the "Identified Receivables"). Schedule I hereto sets forth the Identified Receivables outstanding on the date hereof, and shall be updated on the Closing Date. To the extent all Identified Receivables have not been collected by the 52nd day after completion of the financial assistance described in Section 7.11, Purchaser shall immediately transfer such unpaid Identifiable Receivables to Parent in full satisfaction of the payment of Additional Consideration contemplated by the Agreement.

(b) Following the Closing Date, Parent shall be entitled to receive, when and as received by or on behalf of TDR, all proceeds of the Identified Receivables. The parties agree that TDR shall be entitled to record the payment of the Identified Receivables as revenues in accordance with its revenue recognition policies, and the entitlement of Parent shall be to the proceeds of this receivables.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF SELLER

Except as set forth in the Seller disclosure schedule attached to this Agreement (the "Seller Disclosure Schedule") (with respect to which any particular reference to a section or subsection of this Agreement shall be deemed to be disclosed under all other sections or subsections of this Agreement), each of the Seller and Parent hereby represents and warrants to Purchaser that:

3.1 Organization, Good Standing and Qualification. Parent is a corporation duly organized, validly existing and in good standing under the laws of the State of Utah, and each of Seller and TDR is a limited company duly incorporated and validly existing under the laws of England and Wales. Seller and TDR each has all requisite corporate or similar power and authority to own and operate its properties and assets and to carry on its business as presently conducted and is qualified to do business in each jurisdiction where the ownership or operation of its properties or conduct of its business requires such qualification.

3.2 Capitalization. The Acquired Shares constitute the entire allotted and issued share capital of TDR and are fully paid or credited as fully paid. Seller is the sole legal and beneficial owner of the entire allotted and issued share capital of TDR. The issued shares of TDR are fully paid up and, free from Encumbrances. There are no preemptive or other outstanding rights, options, warrants, conversion rights, redemption rights or repurchase rights to issue or sell any shares of TDR or any securities or obligations convertible or exchangeable into or exercisable for, or giving any Person a right to subscribe for or acquire, any securities of TDR.

3.3 Corporate Authority and Approvals. (a) Each of Parent and Seller has the necessary corporate power and authority and has taken all corporate action necessary in order to execute, deliver and perform its obligations under this Agreement and to carry out and complete the sale of the Acquired Shares. The execution and delivery of this Agreement by Parent and Seller and the consummation by Parent and Seller of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action and no other corporate proceedings on the part of Parent or Seller are necessary to authorize this Agreement or to consummate the transactions contemplated hereby to the extent required under the UBCA or the laws of England or Wales. This Agreement has been duly executed and delivered by both Parent and Seller and, assuming the due authorization, execution and delivery by Purchaser, constitutes a legal, valid and binding obligation of both Parent and Seller, enforceable against Parent and Seller in accordance with its terms, except as such enforceability may be limited in either case by bankruptcy, insolvency, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors' rights generally and by the application of general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

3.4 Title to Shares and Assets. The Seller has marketable title to the Acquired Shares free and clear of all Encumbrances. Except as set forth in Section 3.4 of the Seller Disclosure Schedule, and except for capital leases or security to Parent for advances made to TDR, Seller has marketable title to all of the assets of the Business, free and clear of all Encumbrances, except liens for taxes not yet due and payable.

3.5 Government Filings; No Violations or Conflicts. Except as set forth in Section 3.5 of the Seller Disclosure Schedule, the execution and delivery of this Agreement by Parent and Seller do not, and the performance by Parent and Seller of their respective obligations under this Agreement will not, (i) conflict with or violate the organizational documents of Parent, Seller, or TDR, or (ii) conflict with or violate any law, statute, ordinance, rule, regulation, order, judgment or decree applicable to Parent, Seller or TDR.

3.6 Litigation. No suit, proceeding, hearing or governmental investigation is pending or, to the knowledge of Seller, threatened in writing against Seller or TDR.

3.7 Brokers. Neither Parent, Seller nor any of their executive officers, directors or employees has employed any broker or finder or incurred any liability for any brokerage fees, commissions or finders fees in connection with the transactions contemplated by this Agreement, except that for any agreement with Seven Hills Partners LLC for financial advisory services rendered to Parent at sole expense of Parent.

3.8 Compliance with Laws; Permits. TDR holds all permits, licenses and approvals (none of which has been modified or rescinded and all of which are in full force and effect) from all necessary for TDR to carry on the Business as presently conducted (collectively, the

“Permits”). The Business is not being conducted in material violation of any applicable law, statute, ordinance, regulation, judgment, Permit, order, decree, concession, grant or other authorization of any Governmental Entity.

3.9 Environmental Matters.

(a) In this Section 3.9:

(1) “Dangerous Substance” means any natural or artificial substance (whether solid, liquid or gas and whether alone or in combination with any other substance or radiation) capable of causing harm to any human or other living organism or damaging the Environment, public health or welfare.

(2) “Environment” means the environmental media of air, water and land, all living organisms and natural or man-made structures.

(3) “Environmental Law” means all law in England and Wales relating to the protection of human health or the Environment, the conditions of the workplace or the generation, transportation, storage, treatment, emission or disposal of a Dangerous Substance or Waste.

(4) “Environmental License” means any authorization, license, consent or permission required under any Environmental Law.

(5) “Waste” means any unwanted or surplus substance irrespective of whether it is capable of being recycled or recovered or has any value.

(b) TDR has at all times complied in all material respects with Environmental Law and obtained, and complied with, all Environmental Licenses necessary for carrying on the Business and is not in material breach of any Environmental Law.

(c) The Environmental Licenses necessary for carrying on the Business are in full force and effect and there are no circumstances existing which will give rise to the suspension or revocation of, to lead to the imposition of unusual or onerous conditions on, or to prejudice the renewal of, any of those licenses.

3.10 Labor Matters.

(a) Seller has made available to Purchaser copies of all standard form contracts and handbooks and policies which apply to the employees, officers and directors of TDR.

(b) There is no outstanding claim against TDR by any Person who is now or has been an employee or officer of TDR.

(c) TDR is not party to any collective bargaining agreement with any trade union or staff association other than as required by government regulation.

(d) TDR has not formally recognized a trade union and is not a party to any agreement with any trade union or group or organization representing employees in respect of its employees.

(e) TDR has not in the last six (6) years provided, or agreed to provide, any loan, gratuitous payment or gratuitous benefit to any of its directors, officers or employees or any of their dependants which remains outstanding.

3.11 Intellectual Property.

(a) For purposes of this Section 3.11, "Business Intellectual Property" means all of the: (i) patents and patent applications; (ii) registered trademarks and trademark applications and material unregistered trademarks; (iii) copyrights; and (iv) registered domain names owned by TDR and used in the Business.

(b) The registrations in connection with the Business Intellectual Property are valid and subsisting, all necessary registration and renewal fees in connection with such registrations have been paid, and all necessary documents and certificates in connection with such registrations have been filed with the relevant authorities for the purposes of maintaining such registrations.

(c) There are no contracts, licenses and agreements between Parent, Seller or TDR, on the one hand, and any other Person, on the other hand, relating primarily to the Business Intellectual Property as to which there is any dispute regarding the scope of such agreement, or performance under such agreement including with respect to any payments to be made or received by TDR thereunder.

(d) Neither Parent, Seller or TDR has received notice from any Person that the operation of the Business, including the design, development, manufacture and sale of products and provision of services infringes the intellectual property of any Person.

(e) To the knowledge of Parent and Seller, no Person is materially infringing any of the Business Intellectual Property.

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser hereby represents and warrants to Seller as follows:

4.1 Organization and Authority.

(a) Purchaser is a corporation duly incorporated, validly existing and in good standing under the laws of the Commonwealth of Virginia. Purchaser has all requisite corporate power and authority to execute and deliver this Agreement and perform its obligations hereunder.

(b) The execution and delivery of this Agreement by Purchaser and the performance of its obligations hereunder, have been duly authorized by all necessary corporate action on the part of Purchaser. This Agreement has been duly executed and delivered by Purchaser and constitutes a valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors' rights generally and by the application of general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

4.2 Compliance with Other Instruments. The execution and delivery of this Agreement by Purchaser and the performance by Purchaser of its obligations hereunder will not (a) conflict with or result in any violation of the organizational documents of Purchaser or (b) conflict with or violate any judgment, decree, law or order applicable to Purchaser.

4.3 Brokers. No finder, broker, agent or other intermediary has acted for or on behalf of Purchaser in connection with the negotiation and consummation of this Agreement or the transactions contemplated hereby.

ARTICLE 5

COVENANTS OF PURCHASER

Purchaser covenants and agrees with Seller as follows:

5.1 Additional Advances. From and after May 14, 2007, Tripos may, in its discretion, make additional advances to support the operation of the TDR business (the "Additional Advance") to a maximum of £100,000 after consulting with Purchaser. Any further advances, whether made by Tripos or the Purchaser shall be made only after consultation with and approval by Tripos and Purchaser. Tripos shall be entitled to require that the Additional Advance be secured by assets of TDR, other than receivables allocated to the computation of "Additional Consideration", as contemplated by Section 2.2(a) and in accordance with applicable English law. Any such advances shall remain obligations of TDR following closing, and shall not be forgiven. Unpaid advances shall bear interest at the rate of 8% per annum, shall be repaid on or prior to June 30, 2007.

5.2 Compliance with English Financial Assistance Laws. Purchaser will take all reasonable steps necessary to assure that the transaction complies with English financial assistance laws, including, if necessary, restructuring the transaction so that such laws shall not be applicable to the transaction and the payments to Parent thereunder and assets of TDR shall not be used to effect these payments.

5.3 Employee Matters. Purchaser shall execute and deliver to Parent for filing the appropriate forms, certificates or other documents, including Purchaser's acknowledgment that it is a successor to the Business, and undertake to obtain any consents required under applicable law, to terminate any liability of Parent or Seller for any unemployment compensation payments required to be made to any state or county (or a fund maintained by it) after the Closing Date with respect to any Employees of the Business.

5.4 Filing Assistance. Purchaser shall, upon request by Parent, furnish Parent with all information concerning itself, its subsidiaries, directors, executive officers and stockholders and such other matters as may be reasonably necessary or advisable in connection with any statement, filing, notice or application made by or on behalf of Parent or Seller to any third party or any Governmental Entity in connection with the transactions contemplated by this Agreement.

5.5 Use of Name. Notwithstanding any other provision of this Agreement, from the Closing Date, Purchaser shall not, without the prior written consent of Parent, utilize the name "Tripos" or any similar name other than in accordance with the terms of the Software License Agreement, dated March 20, 2007, between TDR and Tripos, L.P. (the "License Agreement").

5.6 Proceeds and Revenues. From the date hereof, until Parent shall have received all Proceeds Consideration and Revenue Consideration, Purchaser shall not (i) take (nor permit TDR to take) any action to hinder, or (ii) refrain from taking (or permit TDR to refrain from taking) any commercially reasonable action to facilitate, the collection of the Proceeds Consideration, the Revenue Consideration and the repayment of Advances.

ARTICLE 6

CONDITIONS PRECEDENT TO PURCHASER'S OBLIGATIONS

The obligations of Purchaser to consummate the transactions contemplated by this Agreement are subject to the satisfaction of each of the following conditions prior to or at the Closing, unless specifically waived in writing by Purchaser in advance:

6.1 Representations and Warranties.

- (a) The representations and warranties of Parent and Seller contained in this Agreement shall be true and correct in all respects as of the date of this Agreement.
- (b) Each of Parent and Seller shall have duly performed and complied in all respects with all covenants, agreements and conditions required by this Agreement to be performed or complied with by Seller prior to or at the Closing.
- (c) Seller shall have delivered a certificate executed by a duly authorized officer to Purchaser to the foregoing effect.

6.2 Absence of Litigation. No order, writ, injunction or decree which is binding on Purchaser, Parent and/or Seller and which prohibits Purchaser, Parent and/or Seller from consummating the transactions contemplated hereby shall be in effect; provided that Purchaser shall have used its commercially reasonable efforts to have any such order, writ, injunction or decree lifted and the same shall not have been lifted by any such court or governmental or regulatory agency.

6.3 Consents and Approvals. All governmental and regulatory approvals requisite or appropriate to the consummation of the transactions contemplated herein shall have been obtained (or all applicable waiting periods shall have expired) and shall remain in full force and effect.

6.4 SWERDA Transaction. Parent, Seller, TDR, Purchaser and the South West of England Regional Development Agency ("SWERDA") shall have executed one or more definitive agreements (together, the "SWERDA Arrangement") pursuant to which (i) TDR shall sell to SWERDA, and SWERDA shall subsequently leaseback to TDR, the property at Bude-Stratton Business Park, Bude, Cornwall, EX23 8LY, (ii) SWERDA shall consent to the transactions contemplated hereby, and (iii) SWERDA shall release each of Parent, Seller and TDR from all repayment liabilities and related guaranties.

6.5 DTI Repayment and Consent. Parent and Seller shall have allocated and restricted twenty percent (20%) of the proceeds of the SWERDA Arrangement for the settlement of the grants of the U.K. Department of Trade and Industry ("DTI") listed on Schedule 6.5 and DTI shall have executed one or more definitive agreements, pursuant to which (i) DTI consents to the transactions contemplated hereby and (ii) Parent, Seller, TDR and DTI shall reach a mutually agreeable settlement of obligations under the DTI grants in the amount of £591,000 (including contributions by Tripos not exceeding £71,000), and (iii) DTI shall release each of Parent, Seller and TDR from all repayment liabilities and related guaranties under the DTI grants.

6.6 Equipment Lessor Consent. A consent shall have been obtained from CSI Leasing UK Ltd. (the "Equipment Lessor") with respect to all existing equipment leases between TDR and the Equipment Lessor.

6.7 License Agreement. The License Agreement shall be in full force and effect.

6.8 Board Approval.

The boards of directors of both Parent and Seller shall have approved the execution of this Agreement and the transactions related thereto.

6.9 Prior Intercompany Liabilities. All intercompany liabilities incurred prior to March 19, 2007 between (i) Parent or Seller, on the one hand, and (ii) TDR, on the other hand, will be fully discharged and cancelled in a manner mutually satisfactory to Parent and Buyer.

ARTICLE 7

CONDITIONS PRECEDENT TO SELLER'S OBLIGATIONS

The obligations of Seller to consummate the transactions contemplated by this Agreement are subject to the satisfaction prior to or at the Closing of each of the following conditions, unless specifically waived in writing by Seller in advance:

7.1 Representations and Warranties.

(a) The representations and warranties of Purchaser contained in this Agreement shall be true and correct as of the date of this Agreement.

(b) Purchaser shall have duly performed and complied with all covenants, agreements and conditions required by this Agreement to be performed or complied with by Purchaser prior to or at the Closing.

(c) Purchaser shall have delivered a certificate executed by a duly authorized officer to Parent to the foregoing effect.

7.2 Absence of Litigation. No order, writ, injunction or decree which is binding on Purchaser, Parent and/or Seller and which prohibits Purchaser, Parent and/or Seller from consummating the transactions contemplated hereby shall be in effect; provided that Purchaser shall have used its commercially reasonable efforts to have any such order, writ, injunction or decree lifted and the same shall not have been lifted by any such court or governmental or regulatory agency.

7.3 Consents and Approvals. All governmental and regulatory approvals requisite or appropriate to the consummation of the transactions contemplated herein shall have been obtained (or all applicable waiting periods shall have expired) and shall remain in full force and effect.

7.4 SWERDA Transaction. Parent, Seller, TDR, Purchaser and SWERDA shall have executed the SWERDA Arrangement, pursuant to which (i) TDR shall sell to SWERDA, and SWERDA shall subsequently leaseback to TDR, the property at Bude-Stratton Business Park, Bude, Cornwall, EX23 8LY, (ii) SWERDA shall consent to the transactions contemplated hereby, and (iii) SWERDA shall release each of Parent, Seller and TDR from all repayment liabilities and related guaranties.

7.5 DTI Repayment and Consent. Parent and Seller shall have allocated and restricted twenty percent (20%) of the proceeds of the SWERDA Arrangement for the settlement of the grants of DTI listed on Schedule 6.5 and DTI shall have executed one or more definitive agreements, pursuant to which (i) DTI consents to the transactions contemplated hereby and (ii) Parent, Seller, TDR and DTI shall reach a mutually agreeable settlement of obligations under the DTI grants in the amount of [£591,000], and (iii) DTI shall release each of Parent, Seller and TDR from all repayment liabilities and related guaranties under the DTI grants.

7.6 U.S. Employees. Purchaser shall have made offers of employment to three U.S. employees and employment shall have been accepted in each case in a form that relieves Parent and Seller of all employment obligations to each of such individuals effective upon Closing to the reasonable satisfaction of Parent and Seller.

7.7 UK Executives. Parent and Seller shall have been released from any ongoing obligations with respect to severance and employment agreements of the officers or employees of TDR.

7.8 Board Approval. The board of directors of Purchaser shall have approved the execution of this Agreement and the transactions related thereto.

7.9 Security Interest. Parent, Seller, TDR and Purchaser shall have executed all documents necessary, in the reasonable judgment of Parent, to grant Parent an irrevocable security interest in TDR's receivables outstanding against the repayment of the Advances.

7.10 Identified Receivables. Seller shall deliver an updated Schedule I, identifying all Identified Receivables, which shall supersede the Schedule I attached hereto.

7.11 Financial Assistance Matters. The Purchaser shall procure that TDR shall have complied with all English law financial assistance requirements, to the satisfaction of the Parent and the Seller, and the Purchaser shall procure that TDR shall have delivered to the Parent the items set out in Schedule 7.11, such items to be in a form satisfactory to the Parent and the Seller.

ARTICLE 8

CLOSING

8.1 Closing. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place at the offices of Hogan & Hartson L.L.P., 111 South Calvert Street, Suite 1600, Baltimore, Maryland 21202, on the later of (i) the date of execution hereof and (ii) three (3) Business Days after satisfaction of the conditions set forth in Articles 6 and 7, or at such other location or later date or time as mutually agreed upon by the parties. The date of the Closing is referred to herein as the “Closing Date.”

8.2 Deliveries by Parent and Seller. At the Closing, provided all conditions described in Article 7 have been satisfied, Seller shall execute and deliver to Purchaser the following:

- (a) a transfer of the Acquired Shares duly executed by the Seller in favor of the Purchaser together with the relevant share certificate(s) in respect of such Acquired Shares;
- (b) a copy of the minutes of a duly held board meeting of TDR at which there are duly passed the resolutions set out and contained in board minutes of TDR in the form attached as Exhibit A;
- (c) the organizational documents, statutory books (including registers and minute books), common seals (if any) and all books of account and other records of TDR, complete and (where appropriate) written up to date;
- (d) the certificate required by Section 6.1 hereof;
- (e) such other deeds, bills of sale, endorsements, assignments and other good and sufficient instruments of conveyance and assignment as the parties and their respective counsel shall deem reasonably necessary or appropriate to vest in Purchaser all right, title and interest in, to and under the Acquired Shares.

8.3 Deliveries by Purchaser. At the Closing, (i) the Initial Purchase Price to the Parent. In addition, Purchaser shall execute and deliver to Parent and Seller (i) the certificate required by Section 7.1 hereof; and (ii) such other instruments or documents as may be reasonably requested by Parent or Seller to reflect the consummation of the transactions contemplated hereunder.

8.4 Cost Reimbursement. Each party shall pay their own costs hereunder, except that a party shall be responsible for the other party's expenses, to a maximum of £100,000 if a breach by the other party is the principal reason for failure to close.

ARTICLE 9

MISCELLANEOUS

9.1 Survival of Representations and Warranties. The representations and warranties contained in Articles 3 and 4 of this Agreement shall survive until the Closing Date but shall expire immediately following closing. The covenants in Article 5 and Section 8.4 shall survive closing.

9.2 Publicity. Parent, Seller and Purchaser agree that they will not make any press releases or other announcements with respect to the transactions contemplated hereby, except as required by applicable law, without the prior approval of the other parties, which approval will not be unreasonably withheld.

9.3 Commercially Reasonable Efforts. Each party hereto agrees to use its commercially reasonable efforts to cause the conditions to its obligations hereunder to be satisfied on or prior to the Closing Date and otherwise to consummate the transactions contemplated by the Agreement.

9.4 Further Acts and Assurances. Parent and Seller shall, at any time and from time to time at and after the Closing, upon request of Purchaser and without additional consideration, take any and all steps reasonably necessary to transfer any assets of the Business that Seller has been unable to assign to TDR prior to the Closing Date, and Parent and Seller will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further acts, deeds, assignments, transfers, conveyances and assurances as may be reasonably required for the more effective transferring and conveying the Acquired Shares to Purchaser.

9.5 Notices. Any notice or other document to be given hereunder by any party hereto to any other party hereto shall be in writing and delivered by courier or by facsimile transmission, receipt confirmed, or sent by any express mail service, postage or fees prepaid,

If to Parent or Seller:

Tripos, Inc.
1699 South Hanley Road
St. Louis, Missouri 63144
Facsimile: (314) 647-8108
Attention: John P. McAlister

With a copy to:

Henry D. Kahn, Esq.
Hogan & Hartson L.L.P.
111 South Calvert Street
Baltimore, Maryland 21202
Facsimile: (410) 539-6981

If to Purchaser:

Commonwealth Biotechnologies, Inc.
601 Biotech Drive
Richmond, Virginia 23235
Facsimile: (804) 915-3831
Attention: Paul D'Sylva
Richard J. Freer

With a copy to:

Bradley A. Haneberg, Esq.
Kaufman & Canoles, P.C.
III James Center, 12th Floor
1051 East Cary Street
Richmond, Virginia 23219
Facsimile: (804) 771-5777

or at such other address or number for a party as shall be specified by like notice. Any notice which is delivered in the manner provided herein shall be deemed to have been duly given to the party to whom it is directed upon actual receipt by such party or its agent.

9.6 Construction. This Agreement shall be governed by, and construed and interpreted under, the laws of the state of Delaware, without giving effect to principles of conflicts or choice of law. No provision of this Agreement shall be construed against or interpreted to the disadvantage of any party hereto by any court or other governmental or judicial authority or by any board of arbitrators by reason of such party or its counsel having or being deemed to have structured or drafted such provision. All references in this Agreement to Article(s), Section(s), Schedule(s) or Exhibit(s) shall refer to Article(s), Section(s), Schedule(s) or Exhibit(s) of this Agreement.

9.7 Knowledge. Whenever used herein with respect to Seller or Parent, the term "knowledge" shall mean the actual knowledge of any of the persons listed in Schedule 9.7 as of the date hereof.

9.8 Attachments. Every Schedule and Exhibit referred to in this Agreement is incorporated in this Agreement by this reference. The list immediately following the table of contents hereto contains a list of such Schedules and Exhibits.

9.9 Parties Bound by Agreement. The terms, conditions and obligations of this Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns. Except as hereinafter provided, without the prior written consent of the other party, no party hereto may assign such party's rights, duties or obligations hereunder or any part thereof to any other Person prior to Closing. No other party is intended to be a third party beneficiary of the covenants between the parties set forth in this Agreement.

9.10 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original and all of which shall constitute the same instrument.

9.11 Headings. The headings of the Articles and Sections of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction hereof.

9.12 Modification and Waiver. Any of the terms or conditions of this Agreement may be waived in writing at any time by the party which is entitled to the benefits thereof. No waiver of any of the provisions of this Agreement shall be deemed to or shall constitute a waiver of any other provision hereof.

9.13 Severability. Any provision hereof which is prohibited or unenforceable in any jurisdiction will, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction will not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by law, the parties hereto waive any provision of law which renders any such provision prohibited or unenforceable in any respect.

9.14 Access to Records. For a period of six (6) years after the Closing Date, Parent and its attorneys, accountants and representatives shall, upon reasonable advance notice to Purchaser during normal business hours and without disruption of the business of Purchaser, have reasonable access to all books, accounts, records, documents and information relating to Parent, Seller, TDR or the Business for any periods prior to the Closing Date in the possession or custody of Purchaser (or Purchaser's agents) for the purpose of examining and making copies of all or any portion of such documents. In addition, Parent and its attorneys and representatives shall, upon reasonable advance notice to Purchaser, during normal business hours and without disruption to the business of Purchaser, have reasonable access to employees of the Business with respect to the defense of any on-going litigation or claim against Parent or Seller. A representative of Purchaser may be present at all times during such access and investigation by Parent or its attorneys, accountants and representatives.

9.15 Entire Agreement. This Agreement and the Schedules and Exhibits hereto, together with the documents and instruments delivered pursuant hereto, constitute the entire agreement between the parties hereto pertaining to the subject matter hereof and supersede all prior and contemporaneous agreements, understandings, negotiations and discussions, whether written or oral, of the parties hereto; provided, however, that this provision is not intended to abrogate any other written agreement between the parties executed with or after this Agreement or any written agreement pertaining to another subject matter. No supplement, modification or waiver of the terms or conditions of this Agreement shall be binding unless executed in writing by authorized representatives of the parties hereto.

9.16 Certain Definitions.

- (a) "Business Days" means a day other than a Saturday, Sunday, bank or public holiday in the United Kingdom.
- (b) "Encumbrance" means any lien, security interest, pledge, agreement, claim, charge or encumbrance.
- (c) "Governmental Entity" means any governmental or regulatory authority, domestic or foreign.
- (d) "Intellectual Property" shall mean patents, rights to inventions, utility models, copyrights, trade marks, service marks, trade, business and domain names, rights in trade dress or get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights, moral rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications for and renewals or extensions of such rights, and all similar or equivalent rights or forms of protection in any part of the world.
- (e) "Person" means any individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, Governmental Entity or other entity of any kind or nature.
- (f) "UBCA" means the Utah Revised Business Corporation Act, as amended.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered, all on and as of the date first written above.

TRIPOS, INC.

By: /s/ John P. McAlister

Name: John P. McAlister

Title: President and CEO

TRIPOS UK HOLDINGS LIMITED

By: /s/ John P. McAlister

Name: John P. McAlister

Title: Director

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Paul D'Sylva

Name: Paul D'Sylva

Title: CEO

For further information contact:
Dr Paul D'Sylva
CEO
Commonwealth Biotechnologies, Inc.
858 699 0298

Dr. John P McAlister
CEO
Tripos, Inc.
314 616.4473

Commonwealth Biotechnologies, Inc. Announces Definitive

Agreement to Acquire Tripos Discovery Research Ltd

RICHMOND, VIRGINIA and ST. LOUIS, MISSOURI (May 15, 2007) – Commonwealth Biotechnologies, Inc. (“CBI”) (Nasdaq Capital Market: CBTE) and Tripos, Inc. (“Tripos”) (Nasdaq Global Select Market: TRPS) are pleased to announce that they have entered into a definitive agreement providing for the acquisition of all of the outstanding capital stock of Tripos Discovery Research Ltd (“TDR”).

CBI has agreed to acquire TDR from Tripos and plans to continue to operate TDR from its present base in Bude, Cornwall, England, which provides CBI with a strategic base of operations to enter the European market. The transaction is structured with an up-front payment of \$350,000 followed by payments of up to \$1.8 million from TDR receivables and billings.

Concurrent with this transaction TDR is entering into a sale-leaseback transaction with the Southwest England Regional Development Authority (“SWERDA”) under which TDR will net cash of approximately \$4.16 million, enter into a 12 year lease in Bude, and be released from grant repayment obligations with SWERDA and with the English Department of Trade and Industry.

These transactions are expected to close during the month of May or in early June.

TDR is a leading knowledge driven, drug discovery services business that provides pharmaceutical and biotechnology companies with novel approaches to drug discovery. Applying proprietary computational design and therapeutic medicinal chemistry tools and expertise, TDR is able to reduce drug discovery timelines by up to 30%. In addition, since 1997, TDR has also been offering compound libraries under the LeadQuest® brand, screening libraries under the LeadScreen® brand and custom de novo compound libraries under the LeadSelect® brand.

After a period of significant contraction in 2006 following the completion at the end of 2005 of a \$90M contract with Pfizer, non-Pfizer TDR revenues in 2006 grew to \$6.5M and for 2007 are on track for double digit growth.

Dr Paul D'Sylva, CBI's CEO said that "this acquisition is in line with the CBI's stated objective to create a comprehensive drug-discovery services company. TDR's expertise and proprietary tools in medicinal and synthetic chemistry coupled with CBI's expertise in peptide chemistry, proteomics, immunology and genomics create an excellent foundation upon which to grow an integrated research services company targeting the \$5 billion and growing market for drug discovery outsourcing. The transaction positions CBI for sustained growth through the:

- Realization of cost synergies and revenue synergies that can accelerate cash flow growth;
- Provision of additional sales and marketing expertise with offices the UK and the US; and
- Alignment of business product and service capabilities with industry growth

Dr Dick Freer, Chairman and COO, said that "This is an unique opportunity for CBI to acquire what is acknowledged by clients and competitors alike to be one of the premier drug discovery service companies in the world. The staff and facilities are outstanding and the ability to provide input to our clients at the very beginning of the drug discovery process allows CBI a competitive advantage as the lead candidates are identified and moved through the pipeline to the clinic."

Commenting on the transaction, John P. McAlister, Ph.D., president and chief executive officer of

Tripes, stated: "We are very pleased to enter into this transaction with CBI, whom we view as exceptionally well suited to continue our discovery research business. We believe that our customers and employees will be well served by this affiliation. This is also an important step in our previously announced plans to sell Tripes' operating businesses and proceed with the liquidation of our company, which we hope to conclude later this year."

About CBI

CBI specializes in life sciences R&D outsourcing and offers cutting-edge expertise and a complete array of the most current synthetic and analytical technologies in the areas of bio-defense, laboratory support and contract research. CBI is well positioned to compete in the global market for drug discovery outsourcing with an experienced management team and over 50 highly trained scientific staff located in a world-class laboratory in Richmond, Virginia. For more information visit www.cbi-biotech.com.

About Tripes Inc

In March, 2007, Tripes sold its discovery informatics business and its stockholders approved a plan of dissolution and liquidation for Tripes of which the sale of the discovery research business is an integral part. Further information is available in Tripes' SEC filings available at www.sec.gov.

Forward Looking Statements

This announcement contains forward-looking statements regarding the acquisition of TDR by CBI. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to:

- CBI's ability to use TDR to generate earnings or revenues;
- CBI's ability to effectively utilize TDR's existing sales force; and
- CBI's ability to access new market opportunities in the UK and Europe upon closing of the transaction.

All forward-looking statements are based on information available to CBI on the date hereof, and CBI assumes no obligation to update such statements.

In addition, this press release contains forward-looking statements concerning Tripes including, among other things: (1) the company's ability to complete the sale of its Discovery Research

business; (2) the company's ability to satisfy its creditors out of the proceeds of the sales of its assets and other available resources; (3) the company's ability to offset corporate tax liabilities on the sale of assets through the utilization of net operating loss carryforwards; and (4) the company's ability to distribute any remaining cash to its stockholders. These statements are based upon numerous assumptions that Tripos cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in Tripos's filings with the SEC, including, without limitations, those factors set forth in Tripos's Form 10-K for the fiscal year ended December 31, 2006, and from time to time in Tripos's periodic filings with the SEC. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, Tripos does not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.